证券研究报告·公司点评报告·医药商业 九州通（600998） 2023年报&2024一季报点评：业务转型升级， 2024 年 04月 29日 新三年战略实施成效显著 证券分析师 朱国广 买入（维持） 执业证书：S0600520070004 zhugg@dwzq.com.cn [Table_EPS] 盈利预测与估值 2022A 2023A 2024E 2025E 2026E 股价走势 营业总收入（百万元） 140,424 150,140 166,851 185,171 204,891 同比（%） 14.72 6.92 11.13 10.98 10.65 九州通 沪深300 12% 归母净利润（百万元） 2,085 2,174 4,778 3,415 3,777 9% 6% 同比（%） (14.84) 4.27 119.77 (28.53) 10.61 03 %% -3% EPS-最新摊薄（元/股） 0.53 0.56 1.22 0.87 0.97 -- 96 %% -12% P/E（现价&最新摊薄） 15.39 14.76 6.72 9.40 8.50 --- 211 185 %%% [ [TT aab bl ...

证券研究报告：医药生物 | 公司点评报告 2024年4月28日 股票投资评级 九州通(600998) 经营质量持续提升，创新战略推动“千亿航母”行 买入|维持 稳致远 个股表现  经营质量持续提升，全力推进高质量发展 公司发布 2023 年年报：2023 年公司实现营收 1501.40 亿元 九州通 医药生物 11% （+6.92%），归母净利润21.74亿元（+4.27%），扣非净利润19.60亿 7% 元（+13.06%）。2023年公司扣非净利润实现快速增长。 3% -1% 同时公司发布2024年一季报：2024Q1公司实现营业收入404.72 -5% -9% 亿元（-3.85%），归母净利润 5.38 亿元（-4.19%），扣非归母净利润 -13% -17% 5.22亿元（-9.01%）。公司营业收入、归母净利润、扣非归母净利润 -21% 小幅下降，主要原因是 2023Q1 受流感等季节性疾病因素影响，相关 -25% -29% 品种销量大增，营业收入、净利润等基数较高；而 2024Q1 受季节性 2023-04 2023-07 2023-09 2023-11 2024-02 2024-04 疾病因素 ...

证券代码：600998 证券简称：九州通 公告编号：临 2024-021 九州通医药集团股份有限公司 关于 2023 年度利润分配及资本公积金转增股本预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）公司拟以资本公积金向全体股东每10股转增2.90股，不送红股。截至 2024年3月31日，公司总股本3,908,891,654股，以此计算合计转增1,133,578,580 1 股；本次转股后，公司总股本将增加至5,042,470,234股。 如在本公告披露之日起至实施权益分派股权登记日期间公司总股本发生变 动的，公司拟维持每股分配及转增比例不变，相应调整分配及转增总额。 二、公司履行的决策程序 利润分配及转增比例：每10股派发现金红利2.50元（含税），每10股转 增2.90股，不送红股； 本次利润分配及资本公积金转增股本以实施权益分派股权登记日登记的 总股本为基数，具体日期将在权益分派实施公告中明确； 如在股权登记日前公司总股本发生变动，公司拟维持每股分配及转增比 例不变，相应调整分配及转增总额 ...

九州通医药集团股份有限公司董事会 关于2023年度独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指 引第 1 号—规范运作》等法律法规、规范性文件的要求，九州通医药集团股份有 限公司（以下简称"公司"）董事会就公司在任独立董事曾湘泉先生、汤谷良先 生、艾华先生、陆银娣女士的独立性情况进行评估并出具如下专项意见： 经核查上述人员的任职经历以及其签署的相关自查文件，公司上述在任独立 董事未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任 何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客 观判断的关系，符合《上市公司独立董事管理办法》《上海证券交易所上市公司 自律监管指引第 1 号—规范运作》等相关规则中对独立董事应具有独立性的相 关要求。 九州通医药集团股份有限公司董事会 2024 年 4 月 27 日 ...

九州通医药集团股份有限公司 董事会议事规则 第一条 宗旨 为进一步规范公司董事会的议事方式和决策程序，促使董事和董事会有效地 履行法律法规和公司章程赋予的职责，提高董事会规范运做和科学决策水平，根 据《公司法》《上市公司治理准则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、行政法规、部门规章、规范性文件及《九州通医药集 团股份有限公司章程》（以下简称《公司章程》）等有关规定，制订本规则。 第二条 董事会的组成 董事会由 11 名董事组成，设董事长 1 人，副董事长 3 人，暂不设职工代表 的董事。公司设独立董事 4 名。 董事会可以根据实际需要，聘任公司创始人为名誉董事长及名誉副董事长。 名誉董事长及名誉副董事长可列席董事会会议，并就公司重大经营和管理问题提 出建议和质询。 第三条 董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或者减少注册资本、发行债券或其他证券及上市方案； （六）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更公 ...

九州通医药集团股份有限公司 2023年度独立董事述职报告（陆银娣） 2023 年度，作为九州通医药集团股份有限公司（以下简称：公司）的独立 董事，我严格按照《公司法》《上市公司治理准则》《上海证券交易所股票上市规 则》《上市公司独立董事管理办法》及《公司章程》《独立董事制度》的规定，忠 实履行职责，积极出席公司历次董事会、股东大会和董事会专门委员会会议，认 真审议各项议案，对重要事项发表独立意见，运用各自的专业知识，为公司的科 学决策和规范运作提出意见和建议，充分发挥了独立董事对公司的监督、建议等 作用，切实维护了公司和全体股东的合法权益。现将本人在 2023 年度履行独立 董事职责的情况汇报如下： 一、独立董事的基本情况 （一）本人工作履历、专业背景以及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了 丰富的经验。本人工作履历、专业背景以及兼职情况如下： 本人陆银娣， 62 岁，中国国籍，无境外居留权，高级管理人员工商管理证 书。曾任苏州药品监督管理局对外经济和合作科副科长、苏州医药对外贸易公司 总经理、美国礼来制药中国亚洲公司全国高级商务总监、礼来贸易公司总经理、 北京万户良方 ...

Financial Performance - Company's operating revenue reached a historical high of 150.14 billion yuan, a year-on-year increase of 6.92%[2] - Non-GAAP net profit attributable to the parent company was 1.96 billion yuan, a year-on-year increase of 13.06%[2] - Operating cash flow reached a record high of 4.748 billion yuan, a year-on-year increase of 19.10%[2] - Revenue for 2023 reached 150.14 billion RMB, a 6.92% increase compared to 2022[27] - Net profit attributable to shareholders in 2023 was 2.17 billion RMB, up 4.27% year-over-year[27] - Operating cash flow increased by 19.10% to 4.75 billion RMB in 2023[27] - Total assets grew by 0.52% to 92.79 billion RMB at the end of 2023[27] - Basic earnings per share rose 7.84% to 0.55 RMB in 2023[28] - Weighted average return on equity (ROE) increased by 0.06 percentage points to 9.04% in 2023[28] - The company achieved operating revenue of 150.14 billion yuan, a year-on-year increase of 6.92%, and net profit attributable to the parent company of 2.174 billion yuan, a year-on-year increase of 4.27%[172] - The company's main business revenue reached 149.981 billion yuan, a year-on-year increase of 6.91%, with a gross profit of 12.049 billion yuan, a year-on-year increase of 10.48%[173] Business Segments and Revenue Growth - The company's pharmaceutical industry self-produced and OEM business sales revenue reached 2.476 billion yuan[4] - The company's total agency brand promotion business (CSO) sales revenue reached 19.584 billion yuan, a year-on-year increase of 52.45%[5] - The company's pharmaceutical total agency brand promotion business sales revenue reached 10.696 billion yuan, a year-on-year increase of 60.82%[5] - The company's medical device total agency brand promotion business sales revenue reached 8.888 billion yuan, a year-on-year increase of 31.44%[5] - Total agency brand promotion business revenue grew 46.01% in 2023, with a 52.45% increase in gross profit[30] - Pharmaceutical new retail business revenue increased by 10.95% in 2023[30] - Digital logistics technology and supply chain solutions revenue grew 28.45% in 2023, with a 49.44% increase in gross profit[30] - Total agency brand promotion business revenue reached 19.584 billion yuan, a year-on-year increase of 46.01%[40] - Pharmaceutical new retail business revenue increased by 10.95% year-on-year[40] - Digital logistics technology and supply chain solutions revenue increased by 28.45% year-on-year[40] - Total agency brand promotion business (CSO) achieved sales revenue of 19.584 billion yuan, a year-on-year increase of 46.01%, with a gross profit of 2.789 billion yuan, up 52.45% year-on-year[43] - Pharmaceutical total agency brand promotion business achieved sales revenue of 10.696 billion yuan, a year-on-year increase of 60.82%, with a gross profit of 2.267 billion yuan, up 54.83% year-on-year[43] - Medical device total agency brand promotion business achieved sales revenue of 8.888 billion yuan, a year-on-year increase of 31.44%, with a gross profit of 522 million yuan, up 42.91% year-on-year[44] - Pharmaceutical industry self-production and OEM business achieved sales revenue of 2.476 billion yuan, with a gross profit margin of 23.84% and a gross profit of 590 million yuan[45] - JiuXin Traditional Chinese Medicine Group achieved self-production sales revenue of 1.2 billion yuan, with a gross profit margin of 25.6% and a gross profit of 307 million yuan[46] - Beijing Jingfeng Pharmaceutical Group achieved revenue of 466 million yuan, with 150+ products in production and 8 drugs passing consistency evaluation[46] - The company introduced 98 new high-quality products, including 2 with sales exceeding 100 million yuan and 10 with sales exceeding 10 million yuan[43] - The company completed the upgrade of the "Quanqing Health" brand and implemented the full-case brand upgrade for Kefei[43] - The company focused on developing large surgical, cardiovascular intervention, and IVD national platform distribution businesses, optimizing logistics systems and digital platforms[44] - The company produced 36,234 batches of traceable herbal pieces, with a total annual output of 8,991.44 tons, achieving full traceability in the herbal medicine supply chain[46] - Product sales revenue reached 1.882 billion yuan, with Jiuxin Traditional Chinese Medicine focusing on high-quality and safe products, offering a wide range of categories including precious herbs, fine drinks, and formula drinks[47] - The company has obtained 10 MAH Class II product registration certificates and 25 Class I product filing certificates, with 173 OEM medical device specifications and 424 drug OEM specifications, enhancing product competitiveness through self-developed and OEM products[47] - The "Wan Dian Jia Meng" (10,000 Store Franchise) plan has achieved significant progress, with 21,192 direct and franchise pharmacies by the end of Q1 2024, covering 31 provinces and 293 cities, and a target of over 30,000 stores by 2025[49] - Franchise pharmacy sales revenue reached 3.48 billion yuan, an 83.25% year-on-year increase, with 3,900 professional pharmacies, dual-channel pharmacies, and hospital-side stores, including 3.3 billion yuan in prescription outflow revenue[49] - B2C e-commerce total agency and sales business achieved 1.215 billion yuan in revenue, a 26.8% year-on-year growth, with rapid expansion on new e-commerce platforms like Douyin and Kuaishou[50] - The company's B2B e-commerce terminal sales channel generated 17.326 billion yuan in revenue, with the Yaojiujiu B2B platform achieving 11.241 billion yuan in self-operated transactions and covering 99% of administrative regions[51] - Retail e-commerce platform business revenue reached 6.085 billion yuan, an 11.47% year-on-year increase, with sales to JD.com and Alibaba's self-operated platforms exceeding 4.24 billion yuan, a 16.69% increase[52] - The company's logistics Bb/BC integrated warehousing and distribution system supports efficient supply chain logistics, enabling "zero inventory" for online and offline customers and sharing 100,000 product specifications[52] - The company has completed the "Bb/BC integrated warehousing and distribution" logistics service system, covering 6 "BC integrated warehouses" in Hubei, Shanghai, Guangdong, Beijing, Tianjin, and Zhejiang, and has upgraded 24 logistics centers to "Bb integrated" operations across 24 provinces[53] - The "Bb integrated project" was recognized as a leading case in digital transformation by the China Listed Companies Association and the "2023 Digital Economy Development Typical Case" by the Securities Daily[53] - The company launched the "New Medical" strategy, targeting the 321,000 clinics/outpatient departments in China, aiming to provide integrated supply chain and operational services to enhance terminal control[56] - The internet medical business achieved revenue of 156 million yuan in the reporting period, with 31 target hospitals connected to the prescription transfer platform[57] - The company is advancing the REITs project, planning to use 3.3 million square meters of pharmaceutical logistics assets as underlying assets, with the first batch of assets being the Wuhan logistics center, covering 172,000 square meters[59] - The company's digital transformation strategy has established a comprehensive digital platform, including ERP, logistics, and financial systems, supporting multiple business scenarios such as retail, new medical, and pharmaceutical distribution[61] - The company's financial shared cloud platform and "Bb integrated project" were selected as digital transformation典型案例 by the China Listed Companies Association in 2022 and 2023, respectively[61] - The company's "Bb/BC integrated warehousing and distribution project" was recognized as a "2023 Digital Economy Development Typical Case" by the Securities Daily[61] - The company's digital transformation projects, including the orthopedic smart service platform and retail digital operation platform, have been optimized and implemented[61] - The company aims to transition from a traditional pharmaceutical commercial enterprise to a technology-driven platform service provider through digital transformation[61] - The company's revenue from hospital markets reached 54.139 billion yuan, a year-on-year increase of 11.32%, with 268,600 medical institutions covered[62] - Revenue from tiered hospitals was 38.751 billion yuan, up 9.41% year-on-year, covering over 80% of tiered hospitals nationwide[62] - Revenue from primary medical institutions was 7.425 billion yuan, a year-on-year increase of 21.33%, covering over 60% of community health centers and township hospitals[63] - Revenue from private medical institutions was 7.963 billion yuan, up 12.19% year-on-year, serving major private medical groups[63] - The medical device segment achieved sales revenue of 32.815 billion yuan, a year-on-year increase of 11.66%, with 247,500 product specifications[63] - The company's orthopedic Chang'e intelligent service platform was completed, enhancing data service capabilities in the medical device field[64] - The traditional Chinese medicine (TCM) segment achieved sales revenue of 4.2 billion yuan, a year-on-year increase of 14.02%, with a gross profit of 776 million yuan[65] - The TCM segment covers 31 provinces and has established over 30 TCM production bases, with 40 varieties on the quality traceability platform[65] - The company partnered with leading domestic and foreign pharmaceutical companies, including Huarun Sanjiu, Yangtze River Pharmaceutical, and Novo Nordisk, to provide full-chain digital services[66] - Collaborations with medical device companies such as Mindray, MicroPort, and Philips enabled rapid supply to terminal markets through B2B/B2C/O2O platforms[66] - The company signed a strategic cooperation agreement with Johnson & Johnson, covering surgical, orthopedic, and interventional solutions, with a total value of nearly $500 million[67] - The company's logistics system for the "i Maotai" digital marketing platform achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million[68] - The company's logistics subsidiary, Jiuzhou Logistics, was recognized as one of Maotai Group's 23 strategic suppliers, standing out from over 2,000 suppliers[68] - The company's BC integrated warehouse in Hangzhou achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million, while the Tianjin warehouse achieved a peak daily order volume of 20,000 and a peak monthly order volume of 350,000[68] - The company's logistics subsidiary, Jiuzhou Cloud Intelligence, completed a large-scale modern high-end intelligent pharmaceutical warehousing and logistics center project for Shandong Yiyang Health Group[69] - The company signed a memorandum of cooperation with Vietnam Airlines Logistics and Vietnam International Service and Trade Investment to collaborate on logistics information technology and supply chain solutions[70] - The company held the "2023 Jiuzhoutong Financial Institutions Seminar," inviting 32 major financial institutions to discuss future cooperation directions, including expanding credit lines and innovating credit products[71] - The company formed a joint venture, Hubei Jiuzhou Pharmaceutical Supply Chain Co., Ltd., to promote the development of the pharmaceutical supply chain industry in Hubei Province[73] - The company signed a strategic cooperation agreement with Tencent Health to upgrade digital management services, financial payment services, and business intelligence services[74] - The company established a joint artificial intelligence laboratory with Peking University Wuhan Artificial Intelligence Research Institute to enhance digital management and intelligent supply chain systems[74] - The company donated a total of over 3.4 million yuan to support education in 2023, including the construction of the Egret Kindergarten in Ulanhot, Inner Mongolia[75] - The company's 2022 ESG report was rated "A" by Wind ESG and ranked 2nd in the pharmaceutical business category in the 2023 Huazheng ESG rating[75] - The company donated automatic external defibrillators worth over 180,000 yuan to the Red Cross Society of Yingcheng City, Hubei Province, installed in 12 public places with high foot traffic[75] - The company actively participated in disaster relief efforts, organizing donations for the July 2023 floods in Beijing-Tianjin-Hebei and the December 2023 earthquake in Gansu[75] - The company was awarded the "Charitable Donation Enterprise" honor at the first Hubei Charity Awards in September 2023[75] - The "Opinions of the CPC Central Committee and the State Council on Promoting the Development and Growth of the Private Economy" (31 measures) was issued in July 2023, providing strong policy support for private enterprises like the company[76] - In November 2023, eight government departments jointly issued the "Notice on Strengthening Financial Support Measures to Promote the Development and Growth of the Private Economy", proposing 25 specific measures to support private enterprises[79] - The company, as a leading private enterprise in the pharmaceutical distribution industry, will benefit from the financial support policies, which will reduce financing costs and expand financing channels[80] - By 2025, the national and provincial centralized drug procurement is expected to cover more than 500 varieties[81] - The company's sales revenue in public hospitals has achieved a compound annual growth rate of 10.58% over the past three years, with the number of effective customers rapidly increasing to 13,800[85] - Over 70% of the company's existing business is in pharmacies and third-tier markets, benefiting from the outflow of hospital prescriptions and the flow of chronic disease medications to third-tier markets[85] - The company has actively promoted real-world data research on innovative drugs in private hospitals, fostering collaboration opportunities with innovative drug companies[85] - The "dual-channel" policy has been implemented nationwide, covering 2,612 drugs, with reimbursement ratios mostly ranging from 70% to 80%[88] - The company has expanded its business coverage in public hospitals, significantly benefiting from the centralized procurement policy[85] - The company has leveraged its supply chain advantages to secure distribution rights for centralized procurement products and opportunities for total agency promotion in the out-of-hospital market[86] - The company has been actively promoting the development of innovative drugs in private hospitals, enhancing collaboration with innovative drug companies[85] - The company has seen steady growth in sales scale in private hospitals through improved logistics management and supply chain services[85] - The company has capitalized on the expansion of the retail market due to the "dual-channel" and "outpatient coordination" policies[87] - The company has benefited from the dynamic adjustment of the number of drugs included in the "dual-channel" management, with the minimum number being 169 and the maximum being 529[88] - The number of "dual-channel" pharmacies in Shandong Province is expected to exceed 700 by the end of September 2023, with a fund payment ratio of around 70% and no less than 85% for primary medical institutions[89] - By the end of Q1 2024, the company has expanded its directly operated and franchised pharmacies to 21,192, with 3,900 specialty pharmacies, dual-channel pharmacies, and hospital-adjacent stores (including franchised stores)[91] - The company's Good Pharmacist pharmacies in Wuhan have been included in outpatient统筹 management, benefiting from policies such as "outpatient统筹," "dual-channel," and "seven unifications"[91] - The "clinic filing system" was implemented nationwide in 2023, leading to a potential rapid increase in the number of clinics in China[92] - The number of clinics in China reached 321,000 by the end of 2022, with 59,848 new clinics registered in the past year, a 75% increase year-on-year[93] - The clinic medication market in China is growing at a double-digit rate annually, with a market size approaching 200 billion yuan[93] - Jiuzhou Tong's "New Medical" strategy focuses on building a "Digital Medical + Supply Chain" industrial service platform targeting clinic customers, leveraging its strong supply chain capabilities and advanced information management systems[94] - The strategy includes a smart clinic solution combining auxiliary diagnosis systems, ERP systems, patient management systems, and doctor management systems to improve clinic operational efficiency[94] - Jiuzhou Tong aims to provide a turnkey solution for new clinics and drive business growth by integrating upstream supplier resources in specialized fields such as dentistry, medical aesthetics, and traditional Chinese medicine[94] - China's infrastructure REITs market has seen a series of supportive policies since the pilot program was officially launched in April 2020[95][96] - Key policy milestones include the "Guidelines for Public Offering of Infrastructure Securities Investment Funds (Trial)" in August 2020 and the "14th Five-Year Plan" in March 2021, which emphasized the healthy development of infrastructure REITs[97] - The "Notice on Further Improving the Pilot Work of Infrastructure REITs" in July 2021 highlighted the importance of project quality and long-term healthy development of infrastructure REITs[97] - In January 2022, the Ministry of Finance and the State Taxation Administration introduced tax incentives for REITs, allowing deferred taxation on asset transactions or equity acquisitions during the establishment phase[97] - The "Opinions on Further Revitalizing Existing Assets and Expanding Effective Investment" in May 2022 identified key areas for revitalizing existing assets, including infrastructure projects with large scale, good current returns, or growth potential[97] - The "Outline of the Strategic Plan for Expanding Domestic Demand (2022-2035)" in December 2022 proposed the orderly development of infrastructure REITs to form a virtuous cycle between existing assets and new investments[98] - The total scale of infrastructure REITs in China reached 115.6 billion yuan, including 110.5 billion yuan from initial projects and 5.1 billion yuan from expansion projects[101] - The company has approximately 3.3 million square meters of pharmaceutical logistics storage assets and supporting facilities available for REITs issuance[102] - The Chinese government has introduced multiple policies to support the development of REITs, including expanding the scale of REITs issuance and encouraging private investment[99][100][101] - The company's REITs issuance is expected to provide significant equity-based funding, supporting rapid business development[102] - The Chinese government has issued policies to promote the high-quality development of the REITs market,

2024 年第一季度报告 单位：元 币种：人民币 证券代码：600998 证券简称：九州通 九州通医药集团股份有限公司 2024 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信 息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|-------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 40,472,147,237.18 ...

九州通医药集团股份有限公司 地址：湖北省武汉市汉阳区龙兴西街5号九州通总部大楼 联系电话:027-84683017 客服电话:400-160-0998 传真:027-84451256 九州通医药集团股份有限公司 ESG暨可持续发展报告年九州通 2023 目录 CONTENTS 公司介绍 董事长致辞 关键绩效 01 P002-P008 前 言 关于本报告 更多指标 内容索引 09 P082-P087 附 录 ESG管理 合规经营与风控 恪守商业道德 02 P009-P024 可持续发展治理 应对气候变化 打造绿色供应链 低碳循环运营 03 P025-P034 绿色运营 供应链管理 提升质量管控 重视客户体验 05 P053-P062 全链服务 数字化发展新质力 与上下游共创 07 P071-P078 创新发展 创造多元平等职场 人才吸引与发展 员工福利关怀 职业健康与安全 04 P035-P052 员工成长 支持基层医疗服务 助力乡村振兴 践行社会公益 06 P063-P070 责任公民 加强党建引领 持续丰富家文化 08 P079-P081 党建兴家 前言 关于九州通 | 规模领先 | 实力排名 | 社会影响 ...

九州通医药集团股份有限公司 总经理工作细则 第一章 总 则 第一条 为进一步完善公司法人治理结构，明确总经理的职权、职责，规范总 经理的行为，依据《公司法》和本公司章程，特制定本工作细则。 第二条 公司设总经理 1 名，由董事会聘任或解聘。公司设副总经理若干名， 由董事会聘任或解聘。公司总经理、副总经理、财务总监（财务负责人）、董事会 秘书和业务总裁为公司高级管理人员。 第三条 总经理对董事会负责，组织实施董事会决议，主持公司日常生产经营 和管理工作。 第四条 总经理每届任期三年，连聘可以连任。 （七）决定聘任或者解聘除应由董事会决定聘任或者解聘以外的负责管理人员； （八）董事会授予的其他职权。 第七条 公司副总经理由总经理提名，并经董事会聘任，副总经理协助总经理 开展工作，主要职权如下： 第五条 在公司控股股东、实际控制人单位担任除董事、监事以外其他行政职 务的人员，不得担任公司的高级管理人员。公司高级管理人员仅在公司领薪，不由 控股股东代发薪水。 第二章 总经理的职权 第六条 总经理行使下列职权： （一）主持公司的经营管理工作，组织实施董事会决议，并向董事会报告工作； （二）组织实施公司年度经营计划和投资 ...